DTIL Precision BioSciences, Inc. Earnings per share growth rate in current year
Growing demand for ARCUS platform licenses triggered a sharp spike in earnings per share volatility compared to last year, where 14.70 shows the current value of the metric. Positive momentum is bolstered by partnerships with pharma behemoths to develop new drugs, while strict R&D cost controls and transparent management reporting ensure the financial stability of Precision BioSciences (DTIL).
Financial and market metric breakdowns for Precision BioSciences (DTIL)
- current quotes and average value forecast:
- market capitalization data:
- balance sheet equity data:
- debt and liquidity details:
Debt to Equity Precision BioSciences|DTIL - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient precisionbiosciences.com|DTIL - Company Debts|Debts to Book Value Precision BioSciences, Inc.|DTIL - Company Long-Term Debt|Short-Term Debt Volume Precision BioSciences|Quick Liquidity Indicator precisionbiosciences.com
- earnings and market ratios statistics:
DTIL - Net Profit|Company Profit Forecast Precision BioSciences|DTIL - P/E Multiple|Projected Price to Earnings Ratio Precision BioSciences Inc.|DTIL - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Precision BioSciences, Inc.|DTIL - Operating profit EBITDA|Net earnings per share for the last 12 months Precision BioSciences|DTIL - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months precisionbiosciences.com|DTIL - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Precision BioSciences
Basic company analysis:DTIL Precision BioSciences Inc.
Precision BioSciences is investing colossal resources into the development of the ARCUS platform for precision genome editing. By analyzing the volatility of annual earnings per share, investors assess the efficiency of these R&D expenditures. The metric calculates the percentage deviation of the current EPS from the same period last year. This calculation captures the business scaling rates and its financial maturity. For a portfolio holder, this serves as an indicator of the balance between scientific potential and actual profitability.
Main competitors
TEM - Expected net earnings per share growth this year|Earnings per share growth in current year Qiagen Group|Earnings per share growth rate in current year Isis Pharmaceuticals IONS|Earnings per share growth in current year Repligen Corporation (RGEN)|aviditybiosciences.com - Earnings per share growth this year|CRISPR Therapeutics - Net earnings per share growth this year|Earnings per share increase in current year WGS|Ultragenyx Pharma - Earnings growth in current year|BEAM: Earnings per share growth in current year|SRPT: Earnings growth in current year|TWST - Expected net earnings per share growth this year|Earnings per share growth in current year 10x Genomics|Earnings per share growth rate in current year Intellia Therapeutics Inc NTLA|Earnings per share growth in current year Stoke (STOK)|Expected net earnings per share growth this year BioLife|Earnings growth in current year WVE (Wave Life Sciences)|MAZE - Net earnings per share growth this year|Sionna Therapeutics - Earnings growth in current year|Expected net earnings per share growth this year Prime Medicine Inc PRME|TSHA: Earnings growth in current year|Earnings per share growth rate in current year uniQure Pharma (QURE)|Earnings per share growth in current year MeiraGTx Holdings plc|Earnings per share growth this year RGNX (regenxbio.com)|Earnings growth in current year SLDB|Net earnings per share growth this year Ocugen Inc OCGN|Earnings growth in current year PACB (Pacific Biosciences of California)|Benitec Corp (BNTC) - Earnings per share growth rate in current year|DSGN - Earnings per share growth in current year|Expected net earnings per share growth this year rocketpharma.com RCKT|FDMT: Earnings growth in current year|Earnings per share growth this year LXEO|Net earnings per share growth this year KRRO|EDIT (Editas Corp) - Net earnings per one share growth for the current year|Earnings growth in current year SLN|Expected net earnings per share growth this year proqr.com|Earnings per share growth in current year Codexis CDXS|Sangamo Therapeutics Inc. - Earnings per share growth in current year|Nautilus Biotechnology Inc - Earnings growth in current year|MGX (Metagenomi Therapeutics) - Earnings per share growth this year|generationbio.com (GBIO) - Earnings per share growth in current year|Earnings per share growth this year BOLD|XCUR (Exicure Inc.) - Earnings growth in current year|Earnings growth in current year Celsion Corporation|Earnings per share growth in current year Phio Pharmaceuticals (PHIO)|MBIO: Earnings per share trend in current year|Earnings per share growth in current year TransCode Therapeutics, Inc. RNAZ|Earnings per share increase in current year BNGO|Applied DNA Sciences, Inc. - Earnings growth in current year|Earnings per share growth rate in current year bluebird bio Inc.|IPA: Earnings growth in current year|Net earnings per share growth this year Omega Therapeutics Corp|OMIC (Singular Genomics Systems) - Earnings growth in current year|regulusrx.com (RGLS) - Expected net earnings per share growth this year|Earnings per share growth in current year Syros Pharmaceuticals, Inc. (SYRS)|Expected net earnings per share growth this year Telesis Bio Inc.|Earnings growth in current year TCON (TRACON)|Expected net earnings per share growth this year Unity Biotechnology, Inc (UBX)
